BioAlliance acquires European Rights for Ondansetron Oral Spray

BioAlliance Pharma SA a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has announced that it has acquired the European commercial rights to ondansetron Oral Spray (OS) from NovaDel Pharma Inc.

Ondansetron is the leading 5-HT3 antagonist largely used to prevent nausea and vomiting after chemotherapy, radiation, and surgery (tablets or intravenous forms).

Upon successful development and approval, ondansetron OS could be the first anti-emetic to be available in Europe in an oral spray formulation.

The convenience of drug delivery via an oral spray may be an alternative to improve the quality of life of patients suffering from severe nausea and vomiting.

Anti-emetic therapies constitute the largest segment of the supportive care market in the EU and Ondansetron is, by far, the prescription leader in the category.

Under the terms of the Agreement, BioAlliance paid NovaDel a license fee of $3 million upon closing.

NovaDel is eligible for additional milestone payments totalling $24 million (an approval milestone of $5 million and sales-related milestone payments of $19 million) as well as a royalty on net sales.